Company: RCUS
Filing Date: 2025-10-28
Form Type: 10-Q
Source: 0001724521-25-000116
Chunk: 198

Company: Arcus Biosciences, Inc.
Filing Date: 2025-10-28
Form: 10-Q
Item: Part I, Item 1
Chunk 198
---
Nine Months EndedSeptember 30,20252024Cash flow from operating activitiesNet loss$(247)$(189)Adjustments to reconcile net loss to net cash used in operating activities:Stock-based compensation expense45 59 Depreciation and amortization7 7 Noncash lease expense5 5 Impairment of long-lived assets— 20 Amortization of discounts on marketable securities(10)(19)Other items, net2 2 Changes in operating assets and liabilities:Receivable from collaboration partners ($6 and $18 from a related party)9 32 Other assets ($— and $6 from a related party)5 16 Accounts payable ($29 and $— to a related party)24 (2)Deferred revenue (($214) and ($20) to a related party)(214)(14)Other liabilities12 13 Net cash used in operating activities(362)(70) Cash flow from investing activitiesPurchases of marketable securities(679)(871)Proceeds from maturities of marketable securities858 726 Proceeds from sales of marketable securities70 15 Purchases of property and equipment(1)(5)Net cash provided by (used in) investing activities248 (135) Cash flow from financing activitiesProceeds from issuance of common stock ($14 and $228 from a related party)150 228 Proceeds from debt issuances, net49 47 Proceeds from issuance of common stock pursuant to equity award plans3 6 Payments of employee taxes related to net settlement of equity awards— (2)Net cash provided by financing activities202 279 Net increase in cash, cash equivalents and restricted cash88 74 Cash, cash equivalents and restricted cash at beginning of period153 130 Cash, cash equivalents and restricted cash at end of period$241 $204 

See accompanying notes.

5

ARCUS BIOSCIENCES, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(unaudited)

Note 1. Organization, liquidity and capital resources

Organization Arcus Biosciences, Inc. (referred to as "Arcus," "we," "our," "us," or the "Company") is a clinical-stage biopharmaceutical company focused on creating best-in-class therapies. Using our robust and highly efficient drug discovery capability, we have created a significant portfolio of investigational products which are in clinical development, with our most advanced